Neurodevelopmental disability represents a collection of clinically and biologically heterogeneous disorders. However, when a genetic disorder lacks distinguishing clinical features, it has proven challenging to stratify populations of affected individuals for phenotypically driven gene discovery. A recent strategy that has proven powerful for discovering disease-associated genes among more clinically heterogeneous populations has been large wholeexome sequencing studies on individuals presenting with relatively non-specific clinical features and identifying genes with excess de novo mutations in the affected population. [1] [2] [3] Clinical sequencing labs are finding that a third of individuals recruited for undiagnosed genetic disorders are later diagnosed on the basis of the results of trio whole-exome sequencing and that the majority are explained by pathogenic de novo mutations. [3] [4] [5] [6] Here, we describe 13 individuals (Table 1) with a previously unrecognized genetic condition characterized by global developmental delay (13/13), hypotonia (11/13), seizures (10/13), ophthalmological manifestations (8/13), and growth delay (6/13) accompanied by additional variable symptoms (Table 2) . Clinical summaries for all 13 affected individuals are available in the Supplemental Note. These 13 individuals were found to have a de novo missense mutation in GNB1 (MIM: 139380), the gene encoding guanine nucleotide-binding protein (G protein) subunit beta-1 (Gb).
GNB1 encodes a ubiquitously 7 present b subunit of heterotrimeric G proteins, formed by its association with subunits Ga and Gg, which are essential to the signaling function of G-protein-coupled receptors (GPCRs). The association between Ga and Gbg covers the interaction sites on both the a subunit and the Gbg dimer, thus preventing effector interactions and rendering the G protein inactive.
A ligand binding to the GPCR promotes activation where Ga disassociates from the Gbg dimer and the GPCR. The disassociation makes Gbg free to regulate various effector proteins and signaling cascades, including interactions with a variety of enzymes and ion channels. Some effectors directly regulated by Gbg include activation of adenylyl cyclase 2, interactions with b-adrenergic receptor kinase 1, inhibition of calcium channels, activation of potassium channels, activation of phospholipase C-b2, and activation of class IB phosphoinositide 3-kinases. 8 Yoda and colleagues recently used proteomic analysis to show that The American Journal of Human Genetics 98, 1-10, May 5, 2016 3 15, 16 Moreover, embryos homozygous for mutant Gnb1 show an excess of neurological phenotypes (including abnormal brain morphology, decreased cell proliferation, exencephaly, decreased brain size, abnormal neural plate morphology, abnormal embryonic neuroepithelium morphology, abnormal neuronal precursor proliferation, abnormal cortical ventricular zone morphology, and abnormal neuron differentiation), whereas pups without neural-tube defects surviving up to postnatal day 2 also display thin cerebral cortex and abnormal suckling behavior.
15
GNB1 is found deleted in some individuals with chromosome 1p36 deletion syndrome (MIM: 607872), which includes intellectual disability, developmental delay, seizures (including infantile spasms), and muscular hypotonia. Five individuals with 200-823 kb overlapping 1p36.33 deletions were reported to have classic features of the 1p36.33 syndrome. 17 The smallest region of overlap found across the five individuals was a 174 kb stretch including GNB1, CALML6, TMEM52, C1ORF222, and KIAA1751.
17
The clinical features most commonly shared (by more than two of the five individuals) included straight eyebrows (n ¼ 3), a broad nasal root (n ¼ 3), a pointed chin (n ¼ 3), abnormally low-set ears (n ¼ 4), developmental delay (n ¼ 5), expressive-language problems (n ¼ 4), behavioral problems (n ¼ 4), and neonatal hypotonia (n ¼ 3). Our 13 individuals do not share the dysmorphologies reported among these individuals with 1p36.33 syndrome, but they do share neurodevelopmental and seizure features. Because the disease-associated gene is not yet known, this work further suggests that GNB1 is a good candidate for playing a causal role in 1p36.33 syndrome. However, unlike the existing mouse knockout models and the human 1p36.33 deletion syndrome, which represent possible GNB1 haploinsufficient phenotypes, the existing functional studies performed by Yoda and colleagues showed that some of our 13 missense de novo mutations within the Gbg interaction region act as activating mutations that enhance or continuously activate downstream signaling pathways.
9
Our 13 unrelated individuals with a de novo germline mutation in GNB1 range from 13 months to 20 years of age (Table 1 and Supplemental Note). Six of the individuals had trio whole-exome sequencing (WES) performed after written informed consent was obtained through an institutional-review-board-approved research study at the Institute for Genomic Medicine at Columbia University (protocol AAAO8410, individuals 1-3), Centre Hospitalier Universitaire Nantes (individual 4), the Department of Pediatrics at the University of Washington (protocol 48919, individual 5), and the University of Melbourne (H2007/02961, individual 6).
For all six trios, DNA was extracted from maternal, paternal, and proband samples, exome sequenced on a HiSeq 2500 with the Kapa Biosystem's Library Preparation Kit, and whole-exome captured with Nimblegen SeqCap EZ v. Figure S1B ). For individuals 1-3, qualifying variants were identified on the basis of four main modes of inheritance: compound heterozygous, newly homozygous, X-linked hemizygous, and putatively de novo ( Figure S1 ). 4 We found that individual 1 had three, individual 2 had four, and individual 3 had two qualifying genotypes. Individuals 4 and 5 had two qualifying genotypes, whereas individual 6 had only the single qualifying genotype (Table S2) . For individuals 7-13, only the probands were sequenced with the proband-only exome sequencing approach from Baylor Miraca Genetics Laboratories (BMGL). 5, 18 Upon identification of the GNB1 de novo mutations in individuals 1-6, the probands and parents of trios 7-13 were Sanger sequenced for the GNB1 missense variants, and this showed that the variants had arisen de novo in these seven additional individuals. 12, c.239T>C (p.Ile80Thr) in individuals 4, 10, and 11, c.284T>C (p.Leu95Pro) in individual 13, c.301A>G (p.Met101Val) in individuals 5 and 8, and c.976G>A (p.Ala326Thr) in individual 6. We found that the Combined Annotation Dependent Depletion (CADD) score predicted all GNB1 de novo missense mutations affecting our 13 individuals to be among the 1% most deleterious substitutions in the human genome (Table S3) . 19 A list of Human Phenotype Ontology (HPO) 20 terms
were defined for each of the 13 individuals (Table S4) . For three GNB1 residues, we were able to use the HPO terms to ask whether individuals sharing a GNB1 substitution also share certain features more often with each other than with individuals affected at other GNB1 residues. We found that four of the five individuals with a p.Ile80 substitution reported growth delay (HP: 0001510), whereas six of the remaining eight individuals did not. Both dystonia and dysphagia were shared among two of five individuals with a p.Ile80 substitution but were not reported among the other eight individuals. The two individuals sharing a p.Met101 substitution were both diagnosed with autism spectrum disorder, which was not assigned among the remaining 11 individuals. These two individuals with a p.Met101 substitution were phenotyped at different recruitment sites. A single person (individual 3) also presented with polymicrogyria, a rare brain malformation frequently resulting from mutations affecting the PI3K-AKT-mTOR pathway. 21 Although these genotypephenotype correlations are suggestive, reliably determining the phenotypic consequences of the different mutations will require a larger number of individuals with GNB1-related neurodevelopmental disease. The identification of multiple missense de novo mutations in GNB1 is remarkable given that GNB1 is significantly depleted of functional variation in the general population-suggesting that GNB1 might be under strong purifying selections as a result of critical homeostatic roles. Using the ExAC reference cohort, we tallied the unique GNB1 consensus coding sequence (CCDS) protein-coding variants at 105 and the subset considered non-synonymous at 29 (27.6%). Given the sequence context of GNB1, we expect that 77.6% of all simulated (possible) GNB1 variants would result in a non-synonymous effect. Thus, it is clear from the standing variation in the human population that GNB1 is under strong purifying selection (p ¼ 2.1 3 10 À27 , two-tailed binomial exact test). Multiple genic-intolerance metrics consistently support the premise that GNB1 is intolerant to functional variation. 22-24 However, to formally assess whether we have securely implicated GNB1 as a gene associated with disease, we adopted the framework established in the large trio sequencing efforts that have focused on estimating the mutation rate in genes and then asking whether the observed total burden of de novo mutations is beyond what could be explained by chance. 1,2,25,26 The total subject base from which our 13 individuals were identified is 5,855 individuals recruited from multiple sequencing clinics that have ascertained individuals with a presumed genetic disorder of unknown cause. Using the underlying mutation rate of GNB1, 27 we calculated the probability of observing 13 or more de novo mutations by chance among 5,855 individuals to be p ¼ 7.1 3 10 À21 , which survives correction for the 18,669 protein-coding genes routinely tested in exome sequencing by approximately 15 orders of magnitude. Importantly, and independently of whether GNB1 is considered an intolerant gene, this means that GNB1 is now securely implicated as a genome-wide-significant disease-associated gene after we account for all considered individuals; however, the fact that GNB1 is intolerant makes the mutational excess more remarkable, as does the clear localization of the mutations that cause disease. Nine of the 13 GNB1 mutations affect a residue coded for in exon 6 (chr1: g.1737912-1737979; GRCh37). Exon 6 represents only 6.4% of the total GNB1 protein-coding sequence, and therefore finding 9 of the 13 mutations in this exon by chance is highly improbable (p ¼ 1.0 3 10 À8 , two-tailed binomial exact test). The nine de novo GNB1 (GenBank: NM_002074.4) mutations in exon 6 affect closely spaced residues: p.Asp76Gly, p.Asp76Glu, p.Gly77Ser, p.Lys78Arg, p.Ile80Asn, and p.Ile80Thr (Figure 1 ). The stretch of sequence that overlaps exon 6 is known to be the sequence relevant for the interaction between Ga and Gbg in the G protein complex. 8 Recently, GNB1 somatic mutations were found to associate with hematological transformation and also with therapeutic resistance to different kinase inhibitors in the presence of additional driver oncogenic mutations. 9 Yoda and colleagues identified a catalog of 113 somatic mutations from tumor sequencing collections (83 unique variants), available in Table S1 from Yoda et al. 9 In particular, among their identified catalog of mutations, they identified five GNB1 and GNB2 (MIM: 139390) loci that they highlighted as sites of recurrent (more than two) somatic missense mutations. The five residues affected by somatic mutations were Lys57 (11 mutations), Lys78 (three mutations), Ile80 (eight mutations), Lys89 (four mutations), and Met101 (three mutations). All five of these residues are located along the Gb protein surface that interacts with Ga subunits and downstream effectors. 8 Remarkably, 8 of our 13 individuals have a germline de novo GNB1 missense mutation that overlaps one of these five recurrent oncogenic amino acid residues (Figure 1 ). 9 Through multiple lines of functional evidence, Yoda and colleagues showed that these recurrent somatic missense mutations confer cytokine-independent growth and activate canonical G protein signaling downstream of G proteins through the disruption of the Ga-Gbg interaction interface and downstream effector interaction interfaces. 9 One of the mutations evaluated by Yoda and colleagues causes a p.Ile80Thr substitution-observed in 3 of our 13 individuals; through tandem affinity-purification and mass-spectrometry analyses using tagged wild-type and p.Ile80Thr proteins, they demonstrated that the mutant p.Ile80Thr protein had reduced binding to almost all Ga subunits. Interestingly, among their data, they were also able to show that different GNB1 alleles affected different protein interactors, suggesting variable downstream consequences of different GNB1 mutations. 9 The secure implication of GNB1 as a neurodevelopmental-disease-associated gene will enable future research to determine the biology of how mutations in GNB1 contribute to the pathogenesis of neurodevelopmental disease. Although none of our 13 individuals have a reported malignancy, risk of malignancy is something that warrants observation as the individuals are prospectively followed. Also, this wouldn't be the first time that an oncogene has been implicated in a developmental disorder. For example, mutations in genes that encode key components or regulators of pathways that can be found constitutively activated in many types of cancer (such as genes associated with RASopathies, the SWI-SNF complex, and the PI3K-AktmTOR pathway) are also known to be responsible for multiple groups of developmental disorders. BRAF (MIM: 164757) is one example in which somatic mutations are known to cause various cancer types, whereas germline mutations are a known cause of developmental disorders such as cardiofaciocutaneous syndrome (MIM:115150), Noonan syndrome (MIM: 613706), and LEOPARD syndrome (MIM: 613707). Moreover, there is evidence that a subset of BRAF mutations can cause both developmental disorders and cancer (c.1789C>G [p.Leu597Val] [ClinVar: 13969; GenBank: NM_004333.4]). To explore this further, we took the list of 53 BRAF missense mutations that were found to be recurrent (i.e., more than two observations reported among the COSMIC catalog of somatic mutation in cancer) 29 and found that 11 (~21%) of the somatic mutations found as recurrent mutations across tumor samples have also been linked to one or more of (B) Molecular representation of a heterotrimeric G protein (Ga, white; Gb, green; Gg, blue) is based on a crystal structure (PDB: ID 1GP2; DOI: http://dx.doi.org/10.2210/pdb1gp2/pdb). 28 The Gb side chains of the four residues affecting a single subject are indicated in yellow, whereas the three recurrently affected residues are indicated in red.
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The seminal work published on the structure of GNB1 provided experimental evidence on 15 GNB1 residuesincluding the precise residues affected in 8 of our 13 individuals-that mediate interactions with both Ga subunits and effector proteins. According to the crystal structures of heterotrimeric Gabg, two Gbg regions of interaction with Ga are localized: the switch interface (Gb residues 57, 59,  98, 99, 101, 117, 119, 143, 186, 228, and 332) 8 This existing literature highlights multiple downstream signaling cascades that are potentially affected by the disruption of these specific residues. Although the relevance remains unclear, eight of our identified mutations affect the GNB1 residues found to be important for inhibition of calcium channels: Leu55, Lys78, Ile80, Met101, Asn119, Thr143, Asp186, and Trp332. 8 By plotting the distribution of disease-associated variants on a model of the structure of GNB1, we observed the tertiary clustering of these substitutions in the Ga-Gbg binding region ( Figure 1B) . Interestingly, the recurring GNB1 germline de novo mutation (c.239T>C [p.Ile80Thr]) found among our 13 individuals has been reported in the ExAC Browser as a low-confidence singleton variant (ExAC variant 1-1737942-A-G). As highlighted by Yoda and colleagues, 9 the mutation causing the p.Ile80Thr substitution is among the most frequent somatic mutations reported in GNB1 tumor genetics. 9 Indeed, as expected, visually assessing the variant calls of the single low-confidence ExAC observation makes it clear that the variant in the ExAC Browser, if not a technical artifact, is a post-zygotic mutation whereby only 10 variant reads out of 76 overlapping reads support the variant (i.e.,~13% of reads support the p.Ile80Thr variant in contrast to the expected 50%; p ¼ 3 3 10
À11
, two-tailed binomial exact test). Although oncogenic mutations that result in strong downstream signaling activation might not be compatible with survival as germline mutations, there is already evidence in Mendelian disease literature that some recurrent oncogenic mutations are viable but result in various developmental disorders.
31,32 It has been suggested that postnatal intervention to reduce Ras-MAPK activity could alleviate symptoms associated with RASopathies. 31 We cautiously speculate that this paradigm might also eventually be applicable to GNB1-related disorders. GNB1 activating mutations studied by Yoda and colleagues were found to be responsive to the introduction of a small-molecule inhibitor of both PI3K and mTOR pathways (BEZ235), which they found suppressed PI3K-mTOR signaling and improved survival of mice with mutant GNB1-induced leukemia. 9 This study highlights how sequencing large collections of undiagnosed individuals allows us to define the variable phenotypes associated with genes such as GNB1. Moreover, many of the GNB1 mutations identified as germline de novo mutations in neurodevelopmental disease have been described as important sites in tumor genetics, 9 suggesting that these mutations occur at mitotically mutable GNB1 residues enriched among known Gb interaction residues. Yet, despite the observed mitotic mutability, this GNB1 sequence remains extremely intolerant to germline functional mutations in the human population.
Accession Numbers
The accession numbers for the GNB1 variants reported in this paper are ClinVar: SCV000266332, SCV000266333, SCV000266334, SCV000266335, SCV000266336, SCV000266337, SCV000266338, SCV000266339, and SCV000266340.
Supplemental Data
Supplemental Data include a Supplemental Note, Supplemental creatine with moderate elevation of choline and mild lactate peak, all deemed non-specific findings. EEG showed burst-suppression. An extensive laboratory evaluation, including metabolic studies (plasma amino acids, urine organic acids, urine acylglycines, plasma lacta/pyruvate, plasma homocysteine, total and free plasma carnitine/ plasma acylcarnitine profile, plasma creatine and guanidinoacetate), and mtDNA testing for small deletions and point mutations, later followed by mtDNA by massively parallel sequencing were normal.
Whole exome sequencing was reported as negative, but revealed a single heterozygous splice allele in PLA2G6 c.1078-1G>A. Deletion/duplication failed to identify a trans allele. Also, Individual 7's phenotype was not considered to be a good match with PLA2G6 associated neurodegeneration with brain iron accumulation 2B. Since then, he has continued with severe global delay and hemiplegia, thought to be due to infarcts acquired during the complex partial status.
Individual 8 (NM_002074.4 c.301A>G p.Met101Val) is a 20 year old woman who was born to non-consanguineous parents of mixed European and fractional Filipino ancestry.
She was delivered at term after an uncomplicated pregnancy. Birthweight was 4.2 kg, length 52 cm and head circumference 36 cm. Apgar scores were 9 and 9. She spoke her first word at approximately 12 months and first walked independently at 17 months. By two years of age she was using two word phrases and approximately 100 words. At age two she was noted to have hypotonia and be sensitive to loud sounds. In the months following, she lost nearly all of her verbal skills. She was diagnosed with autism at 30 months of age. Symptoms at that time included repetitive hand movements and spinning. She experienced a first tonic-clonic seizure at 11 years of age. MRI of the head has been normal most recently at age 19 and previously at ages 3 and 11. An epileptic episode has not been captured on EEG. She had a normal EEG study at age 4; an EEG study at 11 years of age showed rare right temporal In terms of seizures, they are now controlled with medications. First episode when he was 9-years-of-age: An event of right upper extremity flexion and then extension.
Emergency medical services were called and he was found to be unresponsive and Versed was given IV and no further events. During the evaluation, an EEG was performed, which showed multifocal spikes and generalized background slowing, for which Keppra was started. However, there was irritability and dystonic posturing particularly of arms and that was discontinued. Change to trileptal with no adverse reactions. He was well controlled until age 11 when he had 4-5 seizures, described as mainly focal and lasting several seconds. An EEG at that time showed a high-amplitude background with occipital slowing and multifocal epileptiform discharges. At 4 years old, he began having episodes of severe pain, which were thought to be due to intermittent intussusception of segments of the small bowel or from retention of urine due to neurogenic bladder.
Individual 13 (NM_002074.4 c.284T>C p.Leu95Pro) is a 4-year-old girl with intellectual disability, failure to thrive, hypotonia, cleft palate, cortical vision impairment, and pyridoxine responsive seizure disorder born to non-consanguineous parents of Hispanic descent. She was the 3.1 kg product born at 39 weeks via caesarean section secondary to breech positioning. After birth, she remained hospitalized for 1-1/2 weeks secondary to respiratory distress and poor feeding requiring supplemental oxygen and tube feedings. At 2 months, she was re-hospitalized for evaluation of possible apnea, respiratory distress, and gastroesophageal reflux all of which were nondiagnostic. At 4 months, she was hospitalized for global developmental delays, hypotonia, failure to thrive, and possible seizure activity.
EEG and VEEG showed multifocal independent epileptiform discharges arising from both posterior quadrants, most commonly and persistently from the right parietal region. Brain MRI was normal. Extensive metabolic and neurometabolic testing was normal except for CSF pyridoxal-5-phosphate deficiency. Pyridoxal-5-phosphate supplementation provided good seizure control. Three subsequent EEGs were unremarkable demonstrating only rare spike and waves and polyspikes in the bitemporal regions. She was grossly hypotonic until 2 years of age when this progressed to hypotonia of the axis with hypertonia of the extremities. Table S2 . Qualifying Variant Candidates from the trio whole-exome sequencing data a Institute for Genomic Medicine (IGM) Qualifying Variant pipeline is outlined in Figure S1A .
b Nantes Qualifying Variant pipeline is similar to Figure S1A .
c University of Washington (UW) Qualifying Variant pipeline is outlined in Figure S1B . Table S3 . In silico predictions for the GNB1 mutations found among the thirteen cases.
